Clinic Roundup

• Esperance Pharmaceuticals Inc., of Baton Rouge, La., began enrolling patients in a randomized, multicenter Phase II trial of EP-100 plus paclitaxel in advanced ovarian cancer. EP-100 is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that overexpress luteinizing hormone-releasing hormone receptors on their surfaces.